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Conclusion: Early post-prostatectomy salvage radiation 
before the PSA reaches 0.2 ng/mL results in superior bPFS 
compared to those treated later. This strongly suggests that a 
new definition of post-prostatectomy progression is needed. 
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I am honoured to have been invited to give this memorial 
lecture for which there are three main criteria: it is firstly to 
honour Emmanuel van der Scheuren, one of the fathers of our 
society. Secondly it aims to recognise scientific work within 
the field of radiation oncology and thirdly a contribution to 
education through the ESTRO programmes, in which I have 
been privileged to participate for the last 30 years or so. 
The first ESTRO annual conference was held in London in 
1982 and was memorable with the preparations being agreed 
between Emmanuel and Mike Peckham, my boss at the Royal 
Marsden Hospital at the time. I also want to acknowledge 
how dependent we were on many others for support, 
particularly among others for Lea, of whom we are thinking 
with gratitude especially at this time. 
 Scientific breakthroughs usually build on work that others 
have done and there are many examples from within the field 
of radiation oncology which I have experienced particularly in 
my area of research into whole-body irradiation. We work 
with the unchanging laws of physics but technology advances 
all the time and new biological understanding and new agents 
impact on the way in which we practice oncology. 
 I will discuss some of the ways in which progress in 
radiotherapy may occur and consider the factors which 
determine the impact of clinical trials, with particular 
reference to the START trials run by John Yarnold and his 
team. Consensus guidance, such as that contained in the 
ICRU report 50, has changed practice but there is still much 
evaluation work to be done in some areas. In our activity 
currently, process sometimes seems to take precedence over 
everything else, without the evaluation which would validate 
it.  
ESTRO’s contribution to education has been enormous and it 
has been exciting to be involved in the teaching courses and 
publications of ESTRO with its ever-changing and innovative 
approaches .It is good to note that a new era is starting for 
the School. Amongst all the changes in current practice the 
needs of individual patients must remain our priority 
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Because the results obtained with stereotactic radiosurgery 
(SRS) and stereotactic ablative radiotherapy (SABR) have 
been impressive they have raised the question of whether 
classic radiobiological modeling are appropriate for large 
doses per fraction. In addition to objections to the LQ model, 
the possibility of additional biological effects resulting from 
endothelial cell damage and/or enhanced tumor immunity, 
have been raised to account for the success of SRS and SABR. 
However, the preclinical data demonstrate the following: 
1) Quantitative in vivo endpoints, including late responding 
damage to the rat spinal cord, acute damage to mouse skin 
and early and late damage to the murine small intestine, are 
consistent with the LQ model over a wide range of doses per 
fraction, including the data for single fractions of up to 20 
Gy. 
2) Data on the response of tumors to high single doses are 
consistent with cell killing at low doses. Thus the dose to 
control 50% of mouse tumors (the TCD50) can be predicted 
from cell survival curves at low doses and the number of 
clonogenic cells in the tumors. 
Further the clinical data show: 
3) The high local control of NSCLC and of brain metastases by 
SABR and SRS is the result of high radiation doses leading the 
high BED. In other words the high curability is predicted by 
current radiobiological modeling. 
4) Because high doses are required in SABR it is not possible 
to use it in all circumstances (e.g. for tumors close to critical 
normal structures). But because these high doses are needed 
Patient centric approach: myth or fact? 
